Regeneron Pharmaceuticals Inc vs Xpeng Inc - ADR — how do they compare? Regeneron Pharmaceuticals Inc trades at $653.5 (market cap $70.79B), while Xpeng Inc - ADR trades at $12.95 (market cap $12.66B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 5.6× Xpeng Inc - ADR's market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals.
| REGN | XPEV | |
|---|---|---|
Market Cap | $70.79B | $12.66B |
Sector | Health | Consumer Cyclical |
52-Week High | $812.27 | $28.07 |
52-Week Low | $545.46 | $12.09 |
Enterprise Value | $64.74B | $14.78B |
Dividend Yield | 0.56% | — |
Trailing returns across standard periods
Latest headlines on both assets
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →